Is pyruvate an endogenous anti-inflammatory molecule?

Nutrition

Volumn 22, Issue 9, 2006, Pages 965-972

  Das, Undurti N ^a  

^a UND LIFE SCIENCES   (United States)

Author keywords

Critical illness; Cytokines; Glucose; Inflammation; Insulin; Myocardial infarction; Pyruvate; Sepsis; Shock

Indexed keywords

CYCLOOXYGENASE 2; CYTOKINE; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; INTERLEUKIN 6; LACTIC ACID; LIPID; MESSENGER RNA; MIGRATION INHIBITION FACTOR; POTASSIUM; PROTEIN SUBUNIT; PYRUVATE SODIUM; PYRUVIC ACID; PYRUVIC ACID ETHYL ESTER; REACTIVE OXYGEN METABOLITE; SCAVENGER; SYNAPTOTAGMIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; BACTERIAL TRANSLOCATION; CELL GROWTH; CELL PROTECTION; CIRCULATION; CLINICAL TRIAL; COLON MUCOSA; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; CYTOKINE PRODUCTION; DISEASE MODEL; DRUG DEGRADATION; DRUG EFFECT; DRUG EFFICACY; DRUG STABILITY; DRUG STRUCTURE; ENDOTOXEMIA; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE INJURY; HEART PROTECTION; HEMORRHAGIC SHOCK; HUMAN; HYPERNATREMIA; HYPOKALEMIA; ILEUM MUCOSA; IMMUNOMODULATION; INFLAMMATION; INSULIN RESISTANCE; INTESTINE INJURY; INTESTINE MUCOSA; ISCHEMIA; KIDNEY INJURY; LIPID METABOLISM; LIPID PEROXIDATION; LIVER; LIVER PROTECTION; NONHUMAN; OXIDATIVE STRESS; PERMEABILITY; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN TARGETING; RENAL PROTECTION; REPERFUSION INJURY; RESUSCITATION; REVIEW; SEPSIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION; SURGICAL PATIENT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BLOOD GLUCOSE; CRITICAL ILLNESS; CYTOKINES; DISEASE MODELS, ANIMAL; FREE RADICAL SCAVENGERS; HUMANS; INSULIN; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MYOCARDIAL INFARCTION; NF-KAPPA B; PYRUVATES; PYRUVIC ACID; SEPSIS; SIGNAL TRANSDUCTION;

ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 33747170887     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nut.2006.05.009     Document Type: Review

References (91)

1. Hotchkiss R.S., and Karl I.E. The pathophysiology and treatment of sepsis. N Engl J Med 348 (2003) 138-150
2. Toti P., De Felice C., Occhini R., Schuerfeld K., Stumpo M., Epistolato M.C., et al. Spleen depletion in neonatal sepsis and chorioamnionitis. Am J Clin Pathol 122 (2004) 765-771
3. Tracey K.J., Beutler B., Lowry S.F., Merryweather J., Wolpe S., Milsark I.W., et al. Shock and tissue injury induced by recombinant human cachectin. Science 234 (1986) 470-474
4. Tracey K.J., Fong Y., Hesse D.G., Manogue K.R., Lee A.T., Kuo G.C., et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330 (1987) 662-664
5. Hatherill M., Tibby S.M., Turner C., Ratnavel N., and Murdoch I.A. Procalcitonin and cytokine levels. relationship to organ failure and mortality in pediatric septic shock. Crit Care Med 28 (2000) 2591-2594
6. Moore T.A., Lau H.Y., Cogen A.L., Monteleon C.L., and Standiford T.J. Anti-tumor necrosis factor-alpha therapy during murine Klebsiella pneumoniae bacteremia. increased mortality in the absence of liver injury. Shock 20 (2003) 309-315
7. Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., et al. HMGB-1 as a late mediator of endotoxin lethality in mice. Science 285 (1999) 248-251
8. Yang H., Ochani M., Li J., Qiang X., Tanovic M., Harris H.E., et al. Reversing established sepsis with antagonists of endogenous high mobility group box-1. Proc Natl Acad Sci USA 101 (2004) 296-301
9. Wang H., Yang H., Czura C.J., Sama A.E., and Tracey K.J. HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 164 (2001) 1768-1773
10. Das U.N. Lysophosphatidylcholine and ω-3 fatty acids in sepsis. Adv Sepsis 3 (2004) 121-128
11. Das U.N. Role of lipids in sepsis. Crit Care Shock 7 (2004) 87-92
12. Sakaue S., Nishihira J., Hirokawa J., Yoshimura H., Honda T., Aoki K., et al. Regulation of macrophage migration inhibitory factor (MIF) expression by glucose and insulin in adipocytes in vitro. Mol Med 5 (1999) 361-371
13. Waeber G., Calandra T., Roduit R., Haefliger J.A., Bonny C., Thompson N., et al. Insulin secretion is regulated by the glucose-dependent production of islet beta cell macrophage migration inhibitory factor. Proc Natl Acad Sci USA 94 (1997) 4782-4787
14. Das U.N. Is metabolic syndrome X an inflammatory condition?. Exp Biol Med 227 (2002) 989-997
15. Das U.N. Metabolic syndrome X is common in Indians. but, why and how?. J Assoc Physicians India 51 (2003) 987-998
16. Hirokawa J., Sakaue S., Furuya Y., Ishii J., Hasegawa A., Tagami S., et al. Tumor necrosis factor-alpha regulates the gene expression of macrophage migration inhibitory factor through tyrosine kinase-dependent pathway in 3T3-L1 adipocytes. J Biochem (Tokyo) 123 (1998) 733-739
17. Satomi N., Sakurai A., and Haranaka K. Relationship of hypoglycemia to tumor necrosis factor production and antitumor activity. role of glucose, insulin and macrophages. J Natl Cancer Inst 74 (1985) 1255-1260
18. Fraker D.L., Merino M.J., and Norton J.A. Reversal of the toxic effects of cachectin by concurrent insulin administration. Am J Physiol 256 (1989) E725-E731
19. Das U.N. Is insulin an anti-inflammatory molecule?. Nutrition 17 (2001) 409-413
20. Das U.N. Insulin and the critically ill. Crit Care 6 (2002) 262-263
21. Chambrier C., Laville M., Rhzioual Berrada K., Odeon M., Bouletreau P., and Bevlot M. Insulin sensitivity of glucose and fat metabolism in severe sepsis. Clin Sci (Colch) 99 (2000) 321-328
22. Maitra S.R., Wojnar M.M., and Lang C.H. Alterations in tissue glucose uptake during the hyperglycemic and hypoglycemic phases of sepsis. Shock 13 (2000) 379-385
23. Patiag D., Gray S., Idris I., and Donnelly R. Effects of tumor necrosis factor-alpha and inhibition of protein kinase C on glucose uptake in L6 myoblasts. Clin Sci (Colch) 99 (2000) 303-307
24. Vary T.C., Drnevich D., Jurasinski C., and Brennan Jr. W.A. Mechanisms regulating skeletal muscle glucose metabolism in sepsis. Shock 3 (1995) 403-410
25. Revelly J.P., Tappy L., Martinez A., Bollman M., Caveux M.C., Berger M.M., and Chiolero R.L. Lactate and glucose metabolism in severe sepsis and cardiogenic shock. Crit Care Med 33 (2005) 2420-2422
26. Lind L., and Lithell H. Impaired glucose and lipid metabolism seen in intensive care patients is related to severity of illness and survival. Clin Intens Care 5 (1994) 100-105
27. Fan J., Li Y.H., Wojnar M.M., and Lang C.H. Endotoxin-induced alterations in insulin-stimulated phosphorylation of insulin receptor, IRS-1, and MAP kinase in skeletal muscle. Shock 6 (1996) 164-170
28. Dahn M.S., Lange M.P., Mitchell R.A., Lobdell K., and Wilson R.F. Insulin production following injury and sepsis. J Trauma 27 (1987) 1031-1038
29. Zenni G.C., McLane M.P., Law W.R., and Raymond R.M. Hepatic insulin resistance during chronic hyperdynamic sepsis. Circ Shock 37 (1992) 198-208
30. Maitra S.R., Wang S., Brathwaite C.E., and El-Maghrabi M.R. Alterations in glucose-6-phosphatase gene expression in sepsis. J Trauma 49 (2000) 38-42
31. Das U.N. Current advances in sepsis and septic shock with particular emphasis on the role of insulin. Med Sci Monit 9 (2003) RA181-RA192
32. Rusavy Z., Sramek V., Lacigova S., Novk I., Tesinsky P., and Macdonald I.A. Influence of insulin on glucose metabolism and energy expenditure in septic patients. Crit Care 8 (2004) R213-R220
33. Das U.N. Insulin in sepsis and septic shock. J Assoc Phys India 51 (2003) 695-700
34. Van den Berghe G., Wouters P., Weekers F., Verwaest C., Bruyninckx F., Schetz M., et al. Intensive insulin therapy in critically ill patients. N Engl J Med 345 (2001) 1359-1367
35. Lewis K.S., Kane-Gill S.L., Bobek M.B., and Dasta J.F. Intensive insulin therapy for critically ill patients. Ann Pharmacother 38 (2004) 1243-1251
36. Hansen T.K., Thiel S., Wouters P.J., Christiansen J.S., and Van den Berghe G. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 88 (2003) 1082-1088
37. Brix-Christensen V., Andersen S.K., Andersen R., Mengel A., Dylu T., Andersen N.T., et al. Acute hyperinsulinemia restrains endotoxin-induced systemic inflammatory response. an experimental study in a porcine model. Anesthesiology 100 (2004) 861-870
38. Jeschke M.G., Klein D., Bolder U., and Einspanier R. Insulin attenuates the systemic inflammatory response in endotoxemic rats. Endocrinology 145 (2004) 4084-4093
39. Bronsveld W., van Lambalgen A.A., van Velzen D., van den Bos G.C., Koopman P.A., and Thijs L.G. Myocardial metabolic and morphometric changes during canine endotoxin shock before and after glucose-insulin-potassium. Cardiovasc Res 19 (1985) 455-464
40. Tuynman H.A., Thijs L.G., Straub J.P., Koopman P.D., and Bronsveld W. Effects of glucose-insulin-potassium (GIK) on the position of the oxyhemoglobin dissociation curve, 2,3-diphosphoglycerate, and oxygen consumption in canine endotoxin shock. J Surg Res 34 (1983) 246-253
41. Hinshaw L.B., Archer L.T., Benjamin B., and Bridges C. Effects of glucose or insulin on myocardial performance in endotoxin shock. Proc Soc Exp Biol Med 152 (1976) 529-534
42. Das U.N. Insulin. an endogenous cardioprotector. Curr Opin Crit Care 9 (2003) 375-383
43. Das U.N. Is insulin an endogenous cardioprotector?. Crit Care 6 (2002) 389-393
44. Das U.N. Insulin and the critically ill. Crit Care 6 (2002) 262-263
45. van der Horst I.C., Ottervanger J.P., van't Hof A.W., Reiffers S., Miedema K., Hoorntje J.C., et al. The impact of glucose-insulin-potassium infusion in acute myocardial infarction on infarct size and left ventricular ejection fraction (ISRCTN56720616). BMC Med 3 (2005) 9
46. Mehta S.R., Yusuf S., Diaz R., Zhu J., Pais P., Xavier D., et al., CREATE-ECLA Trial Group Investigators. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction. the CREATE-ECLA randomized controlled trial. JAMA 293 (2005) 437-446
47. Mohanty P., Hamoud W., Garg R., Aljada A., Ghanim H., and Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leukocytes. J Clin Endocrinol Metab 85 (2000) 2970-2973
48. Booth G., Stalker T.J., Lefer A.M., and Scalia R. Elevated ambient glucose induces acute inflammatory events in the microvasculature. effects of insulin. Am J Physiol 280 (2001) E848-E856
49. Aljada A., Ghanim H., Saadesh R., and Dandona P. Insulin inhibits NFKB and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab 86 (2001) 450-453
50. Capes S.E., Hunt D., Malmberg K., and Gerstein H.C. Stress hyperglycemia and increased risk of death after myocardial infarction in patients with and without diabetes. a systemic overview. Lancet 355 (2000) 773-778
51. Montgomery C.M., and Webb J.L. Metabolic studies on heart mitochondria. II. The inhibitory action of parapyruvate on the tricarboxylic acid cycle. J Biol Chem 221 (1956) 359-368
52. Sims C.A., Wattanasirichaigoon S., Menconi M.J., Ajami A.M., and Fink M.P. Ringer's ethyl pyruvate solution ameliorates ischemia/reperfusion-induced intestinal mucosal injury in rats. Crit Care Med 29 (2001) 1513-1518
53. Tawadrous Z.S., Delude R.L., and Fink M.P. Resuscitation from hemorrhagic shock with Ringer's ethyl pyruvate solution improves survival and ameliorates intestinal mucosal hyperpermeability in rats. Shock 17 (2002) 473-477
54. Bunton C.A. Oxidation of α-diketones and α-keto-acids by hydrogen peroxide. Nature 163 (1949) 144
55. 2 in vitro and in vivo and reduce menandione-induced DNA injury and cytotoxicity. Am J Physiol Cell Physiol 268 (1995) C227-C236
56. Dobsak P., Courdertot-Masuyer C., Zeller M., Vergely C., Laubriet A., Assem M., et al. Antioxidative properties of pyruvate and protection of the ischemic rat heart during cardioplegia. J Cardiovasc Pharmacol 34 (1999) 651-659
57. Cicalese L., Lee K., Schraut W., Watkins S., Borle A., and Stanko R. Pyruvate prevents ischemia-reperfusion mucosal injury of rat small intestine. Am J Surg 171 (1999) 97-100
58. Deboer L.W.V., Bekx P.A., Han L., and Steinke L. Pyruvate enhances recovery of hearts after ischemia and reperfusion by preventing free radical generation. Am J Physiol Heart Circ Physiol 265 (1993) H1571-H1576
59. Crestanello J.A., Lingle D.M., Millili J., and Whitman G.J. Pyruvate improves myocardial tolerance to reperfusion injury by acting as an antioxidant. a chemiluminescence study. Surgery 124 (2001) 92-99
60. Salahudeen A.K., Clark E.C., and Nath K.A. Hydrogen peroxide-induced renal injury. A protective role for pyruvate in vitro and in vivo. J Clin Invest 88 (1991) 1886-1893
61. Varma S.D., Hegde K.R., and Kovtun S. Oxidative damage to lens in culture. reversibility by pyruvate and ethyl pyruvate. Ophthamologica 220 (2006) 52-57
62. Varma S.D., Hegde K.R., and Kovtun S. Attenuation and delay of diabetic cataracts by antioxidants. effectiveness of pyruvate after onset of cataract. Ophthamologica 219 (2005) 309-315
63. Yu Y.M., Kim J.B., Lee K.W., Kim S.Y., Han P.L., and Lee J.K. Inhibition of the cerebral ischemic injury by ethyl pyruvate with a wide therapeutic window. Stroke 36 (2005) 2238-2243
64. Tawadrous Z.S., Delude R.L., and Fink M.P. Resuscitation from hemorrhagic shock with Ringer's ethyl pyruvate solution improves survival and ameliorates intestinal mucosal hyperpermeability in rats. Shock 17 (2002) 473-477
65. Yang R., Gallo D.J., Baust J.J., Uchiyama T., Watkins S.K., Delude R.L., and Fink M.P. Ethyl pyruvate modulates inflammatory gene expression in mice subjected to hemorrhagic shock. Am J Physiol Gastrointest Liver Physiol 283 (2002) G212-G221
66. Woo Y.J., Taylor M.D., Cohen J.E., Jayasankar V., Bish L.T., Burdick J., et al. Ethyl pyruvate preserves cardiac function and attenuates oxidative injury after prolonged myocardial ischemia. J Thorac Cardiovasc Surg 27 (2004) 1262-1269
67. Mulier K.F., Beilman G.J., Conroy M.J., Taylor J.H., Skarda D.E., and Hammer B.E. Ringer's ethyl pyruvate in hemorrhagic shock and resuscitation does not improve early hemodynamics or tissue energetics. Shock 23 (2005) 248-252
68. Ulloa L., Ochani M., Yang H., Tanovic M., Halperin D., Yang R., et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 99 (2002) 12351-12356
69. Venkataraman R., Kellum J.A., Song M., and Fink M.P. Resuscitation with Ringer's ethyl pyruvate solution prolongs survival and modulates plasma cytokine and nitrite/nitrate concentrations in a rat model of lipopolysaccharide-induced shock. Shock 18 (2002) 507-512
70. Sappington P.L., Han X., Yan R., Delude R.L., and Fink M.P. Ethyl pyruvate ameliorates intestinal epithelial barrier dysfunction in endotoxemic mice and immunostimulated caco-2 enterocytic monolayers. J Pharmacol Exp Ther 304 (2003) 464-476
71. Jeong H.J., Hong S.H., Park R.K., An N.H., and Kim H.M. Ethanol induces the production of cytokines via the Ca(2+), MAP kinase, HIF-1alpha, and NF-kappaB pathway. Life Sci 77 (2005) 2179-2192
72. Latvala J., Hietala J., Koivisto H., Jarvi K., Anttila P., and Niemela O. Immune responses to ethanol metabolites and cytokine profiles differentiate alcoholics with or without liver disease. Am J Gastroenterol 100 (2005) 1303-1310
73. Yang R., Han X., Delude R.L., and Fink M.P. Ethyl pyruvate ameliorates acute alcohol-induced liver injury and inflammation in mice. J Lab Clin Med 142 (2003) 322-331
74. Yang R., Uchiyama T., Watkins S.K., Han X., and Fink M.P. Ethyl pyruvate reduces liver injury in a murine model of extrahepatic cholestasis. Shock 22 (2004) 369-375
75. Harada T., Moore B.A., Yang R., Cruz Jr. R.J., Delude R.L., and Fink M.P. Ethyl pyruvate ameliorates ileus induced by bowel manipulation in mice. Surgery 138 (2005) 530-537
76. Chance B., Sies H., and Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol Rev 59 (1979) 527-605
77. Heinzel B., John M., Klatt P., Bohme E., and Mayer B. Ca2+/calmodulin-dependent formation of hydrogen peroxide by brain nitric oxide synthase. Biochem J 281 pt 3 (1992) 627-630
78. Hassan H.M., and Fridovich I. Intracellular production of superoxide radical and hydrogen peroxide by redox active compounds. Arch Biochem Biophys 196 (1979) 385-395
79. Simizu S., Takada M., Umezawa K., and Imoto M. Requirement of caspase-3(-like) protease-mediated hydrogen peroxide production for apoptosis induced by various anticancer drugs. J Biol Chem 273 (1998) 26900-26907
80. Badwey J.A., and Karnovsky M.L. Active oxygen species and the functions of phagocytic leukocytes. Annu Rev Biochem 49 (1980) 695-726
81. Lu Y., and Wahl L.M. Oxidative stress augments the production of matrix metalloproteinase-1, cyclooxygenase-2, and prostaglandin E2 through enhancement of NF-kappa B activity in lipopolysaccharide-activated human primary monocytes. J Immunol 175 (2005) 5423-5429
82. Dizdaroglu M. Oxidative damage to DNA in mammalian chromatin. Mutat Res 275 (1992) 331-342
83. Holleman A.F. Notice surl'action del'eau oxygénée sur les acides α-cétoniques et sur les diketones 1.2. Recl Trav Chim Pays-bas Belg 23 (1904) 169
84. Hatcher W.B., and Hill A.C. Hydrogen peroxide as an oxidizing agent in acid solution. IX. The oxidation of keto acids. Trans R Soc Can 22 (1928) 211
85. Reitzer L.J., Weiss B.M., and Kennell D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem 254 (1979) 2669-2676
86. Spragg R.G., Hinshaw D.B., Hyslop P.A., Schraufstatter I.U., and Cochrane C.G. Alterations in adenosine triphosphate and energy charge in cultured endothelial and P388D1 cells after oxidant injury. J Clin Invest 76 (1985) 1471-1476
87. O'Donnell-Tormey J., Nathan C.F., Lanks K., DeBoer C.J., and De La Harpe J. Secretion of pyruvate. An antioxidant defense of mammalian cells. J Exp Med 165 (1987) 500-514
88. 2 fixation in adipose tissue. Evidence for regulation of pyruvate transport. J Biol Chem 258 (1983) 483-490
89. Denton R.M., McCormack J.G., and Marshall S.E. Persistence of the effect of insulin on pyruvate dehydrogenase activity in rat white and brown adipose tissue during the preparation and subsequent incubation of mitochondria. Biochem J 217 (1984) 441-452
90. Fink M.P. Ethyl pyruvate. a novel treatment for sepsis and shock. Minerva Anesthesiol 70 (2004) 365-371
91. Liu Y.Q., Jetton T.L., and Leahy J.L. β-cell adaptation to insulin resistance. Increased pyruvate carboxylase and Malate-pyruvate shuttle activity in islets of nondiabetic Zucker fatty rats. J Biol Chem 277 (2002) 39163-39168